149 related articles for article (PubMed ID: 26555995)
1. Intranasal, siRNA Delivery to the Brain by TAT/MGF Tagged PEGylated Chitosan Nanoparticles.
Malhotra M; Tomaro-Duchesneau C; Saha S; Prakash S
J Pharm (Cairo); 2013; 2013():812387. PubMed ID: 26555995
[TBL] [Abstract][Full Text] [Related]
2. Intranasal delivery of chitosan-siRNA nanoparticle formulation to the brain.
Malhotra M; Tomaro-Duchesneau C; Saha S; Prakash S
Methods Mol Biol; 2014; 1141():233-47. PubMed ID: 24567143
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases.
Malhotra M; Tomaro-Duchesneau C; Prakash S
Biomaterials; 2013 Jan; 34(4):1270-80. PubMed ID: 23140978
[TBL] [Abstract][Full Text] [Related]
4. Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes.
Gu J; Al-Bayati K; Ho EA
Drug Deliv Transl Res; 2017 Aug; 7(4):497-506. PubMed ID: 28315051
[TBL] [Abstract][Full Text] [Related]
5. Systemic siRNA Delivery via Peptide-Tagged Polymeric Nanoparticles, Targeting PLK1 Gene in a Mouse Xenograft Model of Colorectal Cancer.
Malhotra M; Tomaro-Duchesneau C; Saha S; Prakash S
Int J Biomater; 2013; 2013():252531. PubMed ID: 24159333
[TBL] [Abstract][Full Text] [Related]
6. Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration.
Gartziandia O; Herran E; Pedraz JL; Carro E; Igartua M; Hernandez RM
Colloids Surf B Biointerfaces; 2015 Oct; 134():304-13. PubMed ID: 26209963
[TBL] [Abstract][Full Text] [Related]
7. Delivery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating peptide-modified nano-micelles.
Kanazawa T; Akiyama F; Kakizaki S; Takashima Y; Seta Y
Biomaterials; 2013 Dec; 34(36):9220-6. PubMed ID: 23992922
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery of small interfering RNA to colon cancer cells using chitosan and PEGylated chitosan nanoparticles.
Rudzinski WE; Palacios A; Ahmed A; Lane MA; Aminabhavi TM
Carbohydr Polym; 2016 Aug; 147():323-332. PubMed ID: 27178938
[TBL] [Abstract][Full Text] [Related]
9. Chitosan-based nanoparticles for survivin targeted siRNA delivery in breast tumor therapy and preventing its metastasis.
Sun P; Huang W; Jin M; Wang Q; Fan B; Kang L; Gao Z
Int J Nanomedicine; 2016; 11():4931-4945. PubMed ID: 27729789
[TBL] [Abstract][Full Text] [Related]
10. Optimization of chitosan nanoparticles as an anti-HIV siRNA delivery vehicle.
Iranpur Mobarakeh V; Modarressi MH; Rahimi P; Bolhassani A; Arefian E; Atyabi F; Vahabpour R
Int J Biol Macromol; 2019 May; 129():305-315. PubMed ID: 30738164
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor effects in mice induced by survivin-targeted siRNA delivered through polysaccharide nanoparticles.
Yang F; Huang W; Li Y; Liu S; Jin M; Wang Y; Jia L; Gao Z
Biomaterials; 2013 Jul; 34(22):5689-99. PubMed ID: 23632321
[TBL] [Abstract][Full Text] [Related]
12. Prolongation of life in rats with malignant glioma by intranasal siRNA/drug codelivery to the brain with cell-penetrating peptide-modified micelles.
Kanazawa T; Morisaki K; Suzuki S; Takashima Y
Mol Pharm; 2014 May; 11(5):1471-8. PubMed ID: 24708261
[TBL] [Abstract][Full Text] [Related]
13. Delivery of siRNA targeting tumor metabolism using non-covalent PEGylated chitosan nanoparticles: Identification of an optimal combination of ligand structure, linker and grafting method.
Corbet C; Ragelle H; Pourcelle V; Vanvarenberg K; Marchand-Brynaert J; Préat V; Feron O
J Control Release; 2016 Feb; 223():53-63. PubMed ID: 26699426
[TBL] [Abstract][Full Text] [Related]
14. Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: preparation and detection in rat brain.
Hanafy AS; Farid RM; ElGamal SS
Drug Dev Ind Pharm; 2015; 41(12):2055-68. PubMed ID: 26133084
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and characterization of Fe
Arami S; Rashidi MR; Mahdavi M; Fathi M; Entezami AA
Hum Exp Toxicol; 2017 Mar; 36(3):227-237. PubMed ID: 27162247
[TBL] [Abstract][Full Text] [Related]
16. A Positioning Device for the Placement of Mice During Intranasal siRNA Delivery to the Central Nervous System.
Ullah I; Chung K; Beloor J; Lee SK; Kumar P
J Vis Exp; 2019 Aug; (150):. PubMed ID: 31475960
[TBL] [Abstract][Full Text] [Related]
17. Intranasal Administration of TAT-Conjugated Lipid Nanocarriers Loading GDNF for Parkinson's Disease.
Hernando S; Herran E; Figueiro-Silva J; Pedraz JL; Igartua M; Carro E; Hernandez RM
Mol Neurobiol; 2018 Jan; 55(1):145-155. PubMed ID: 28866799
[TBL] [Abstract][Full Text] [Related]
18. Robust neuroprotective effects of intranasally delivered iNOS siRNA encapsulated in gelatin nanoparticles in the postischemic brain.
Kim ID; Sawicki E; Lee HK; Lee EH; Park HJ; Han PL; Kim KK; Choi H; Lee JK
Nanomedicine; 2016 Jul; 12(5):1219-29. PubMed ID: 26945975
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and characterization of rabies virus glycoprotein-tagged amphiphilic cyclodextrins for siRNA delivery in human glioblastoma cells: in vitro analysis.
Gooding M; Malhotra M; McCarthy DJ; Godinho BM; Cryan JF; Darcy R; O'Driscoll CM
Eur J Pharm Sci; 2015 Apr; 71():80-92. PubMed ID: 25703259
[TBL] [Abstract][Full Text] [Related]
20. pH-triggered nanoparticle mediated delivery of siRNA to liver cells in vitro and in vivo.
Kolli S; Wong SP; Harbottle R; Johnston B; Thanou M; Miller AD
Bioconjug Chem; 2013 Mar; 24(3):314-32. PubMed ID: 23305315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
